PfizerLong
Ex-dividend date - An end to investors' hesitation?
Good evening.
Price has remained awfully quiet in anticipation of bad headlines. When those headlines actually arrived (23 elderly patients dead in Norway), they were swept under the rug by media world-wide, or just shrugged off.
Source: Bloomberg - Pfizer Vaccine Safe for Elderly Despite Norway Scare, WHO Says
Price has remained extremely stable around 36.22-37.78$ but the ex-dividend date is 28th of January, which means if investors were looking to buy but were hesitant, they'll have to pull the trigger in the coming 2 days or miss out on the dividends of the quarter. Q4 2020 Earnings report is expected on the 2nd of February.
Might be exactly what PFE needs to break out towards 42.50$ again. Especially considering the company's pledge to make 1.3 to 2 billion doses in 2021.
P.S.: Pfizer is looking at a 50% COVID vaccine earnings split with BioNTech, or even slightly more.
Source: Motley Fool - What Does 2021 Hold for BioNTech Stock?
Price has remained awfully quiet in anticipation of bad headlines. When those headlines actually arrived (23 elderly patients dead in Norway), they were swept under the rug by media world-wide, or just shrugged off.
Source: Bloomberg - Pfizer Vaccine Safe for Elderly Despite Norway Scare, WHO Says
Price has remained extremely stable around 36.22-37.78$ but the ex-dividend date is 28th of January, which means if investors were looking to buy but were hesitant, they'll have to pull the trigger in the coming 2 days or miss out on the dividends of the quarter. Q4 2020 Earnings report is expected on the 2nd of February.
Might be exactly what PFE needs to break out towards 42.50$ again. Especially considering the company's pledge to make 1.3 to 2 billion doses in 2021.
P.S.: Pfizer is looking at a 50% COVID vaccine earnings split with BioNTech, or even slightly more.
Source: Motley Fool - What Does 2021 Hold for BioNTech Stock?
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.